Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2026
Event: Entry into a Material Definitive Agreement (Lease) for new headquarters and expanded manufacturing facilities.
Key Financial Metrics and Obligations
This filing details a specific lease agreement rather than periodic financial performance. Key financial terms include:
- Property Size: Approximately 171,000 rentable square feet at 9625 Towne Centre Drive, San Diego, CA.
- Initial Base Rent: $5.60 per square foot, totaling approximately $958,000 per month.
- Rent Escalation: Annual increases of 3.0%.
- Lease Term: 138 months following the rent commencement date.
- Security Deposit: Approximately $958,000 (cash or letter of credit).
- Additional Costs: Capricor is responsible for real property taxes, building insurance, routine maintenance, and operating costs.
Material Changes and Lease Structure
The agreement includes significant rent abatement and contingency provisions:
- Commencement: Estimated to begin on the earlier of the satisfaction/waiver of FDA approval contingencies or December 31, 2026.
- Rent Commencement: Scheduled for 12 months after the lease commencement date.
- Abatement Periods:
- 18 months of full base rent abatement starting on the Rent Commencement Date.
- 6 months of partial abatement where rent is payable on only 128,068 square feet.
- Termination Contingency: If Capricor does not receive FDA approval for Deramiocel (for Duchenne muscular dystrophy) by December 31, 2026, either party may terminate the lease within five business days.
Outlook, Risks, and Management Commentary
Strategic Intent: The new facility will serve as Capricor's headquarters, housing expanded manufacturing cleanrooms, R&D laboratories, and administrative offices.
Risk Factor: The lease is heavily contingent on the regulatory approval of Deramiocel. Failure to secure FDA approval by the specified deadline creates a risk of lease termination and potential disruption to the planned expansion.
Management Commentary: The filing incorporates the full text of the Lease by reference, noting it will be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2026.
Investor Verification Checklist
- Verify the status of the FDA approval application for Deramiocel for Duchenne muscular dystrophy.
- Confirm the exact date the lease contingency is satisfied or waived to determine the actual rent commencement date.
- Review the upcoming Form 10-Q for the full text of the Lease Agreement and the tenant improvement allowance details.
- Assess the company's current liquidity to cover the $958,000 security deposit and future operating costs.